Inpen
Composition
InpenTM 500 mg IV injection: Each vial contains Meropenem USP 500 mg.
InpenTM 1 g IV injection: Each vial contains Meropenem USP 1 g.
Indications
InpenTM is indicated for treatment, in adults and children, of the following infections caused by single or multiple susceptible bacteria and as empiric therapy prior to the
identification of the causative organisms:
Lower Respiratory Tract Infections, Urinary Tract Infections, including complicated infections Intra-abdominal Infections, Gynaecological infections, including
postpartum infections, Skin and Skin Structure Infections, Meningitis, Septicaemia, Empiric treatment, including initial monotherapy, for presumed bacterial
infections in host-compromised, neutropenic patient.
Because of its broad spectrum or bactericidal activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. InpenTM is effective for the treatment of
polymicrobial infections.
Dosage and Administration
ADULTS:
Usual dose: 500 mg to 1 g by intravenous administration every 8 hours depending on type end severity of Infection.
Exceptions: 1. Febrile episodes to neutropenic patients - the dose should be I g every 8 hours. 2. Meningitis- the dose should be 2 g every 8 hours.
As with other antibiotic, caution may be required in using Meropenem as monotherapy in critically iII patients with known or suspected Pseudomonas aeruginosa lower
respiratory tract erections. Regular sensitivity testing is recommended when treating Pseudomonas aeruginosa infections.
InpenTM should be given as an intravenous bolus injection over approximately 5 minutes or by intravenous infusion over approximately 15 to 30 minutes (see Method of
Administration).
ELDERLY
No dosage adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.
CHILDREN
For infants and children over 3 months and up to 12 years of age the recommended intravenous dose is 10 to 40 mg/kg every 8 hours depending on type and severity of
infection, the known or suspected susceptibility of the pathogen(s) and the condition of the patient. In children over 50 kg weight, adult dosage should be used
Itracon
Composition:
Itracon 100 Capsule: Each capsule contains Itraconazole pellets equivalent to Itraconazole
USP 100 mg.
Itracon 200 Tablet: Each film coated tablet contains Itraconazole USP 200 mg.
Itracon Oral Solution: Each 5 ml oral solution contains Itraconazole USP 50 mg.
Pharmacology:
Itracon is a preparation of Itraconazole, an orally active triazole antifungal agent, having broad
spectrum activity and favourable pharmacokinetic profile. Itraconazole inhibits cytochrome
P450 dependent enzymes resulting in impairment of the biosynthesis of Ergosterol, a major
component of the cell membrane of yeast and fungal cells.
Indications:
Itracon Capsule & Tablet: Tinea corporis, Tinea cruris, Tinea pedis, Tinea manuum,
Vulvovaginal candidiasis, Fungal keratitis, Pityriasis versicolor, Oropharyngeal candidiasis,
Onychomycosis, Histoplasmosis, Systemic Infections: Aspergillosis, Candidiasis and
Cryptococcal infection when other drugs are ineffective. Antifungal prophylaxis: To prevent
systemic fungal infection in severely neutropenic patients.
Itracon Oral Solution: It is indicated for the treatment of Oropharyngeal Candidiasis &
Esophageal Candidiasis.
Dosage & Administration:
Itracon Tablet & Capsule:
Tinea corporis, Tinea cruris: 100 mg daily for 2 weeks.
Tinea pedis, Tinea manuum: 100 mg daily for 4 weeks.
Vulvovaginal candidiasis: 200 mg twice daily for 1 day.
Fungal keratitis: 200 mg daily for 3 weeks.
Pityriasis versicolor: 200 mg daily for 1 week.
Oropharyngeal candidiasis: 100 mg daily (200 mg for immuno-compromised patients) for 15
days.
Onychomycosis: 200 mg daily for 3 months; or 200 mg twice daily for 7 days (course),
subsequent courses to be repeated after 21 days interval; fingernails 2 courses and toenails 3
courses.
Histoplasmosis: 200 mg 1-2 times daily.
Systemic Infections: 200 mg once daily (Aspergillosis, Candidiasis and Cryptococcus infection
when other drugs are ineffective), increased in invasive or in cryptococcal meningitis to 200 mg
twice daily.
Antifungal prophylaxis: To prevent systemic fungal infection in severely neutropenic patients
100 mg daily.
Itracon Oral Solution: This solution should be vigorously swished in the mouth (10 ml at a time)
for several seconds and swallowed. The recommended dosage of Itracon oral solution for
Oropharyngeal Candidiasis is 200 mg (20 ml) daily for 1 to 2 weeks. The recommended
dosage of Itracon oral solution for Esophageal Candidiasis is 100 mg (10 ml) daily for a
minimum treatment of 3 weeks. Child Dose: 5 mg / kg once daily for 14 days. For oral use only
(for 1 month to 11 years of age) or as directed by the physician.
Iclear Eye Drops
Composition
Iclear™ Sterile Eye Drops: Each ml contains
Hypromellose BP 3 mg.
Indications
Hypromellose is used to treat dry eye conditions
where reduced or absent of normal lachrymal
secretion. Lachrymal secretions (tears) are
produced to keep the eye lubricated and clean.
Dosage and Administration
Therapy of dry eye syndrome requires an individual
dosage regimen.The usual dose for Iclear is 1 drop
into the conjunctival sac 3 to 5 times per day or as
directed by the physician or as directed by the
physician.
Imigra
Composition
Imigra™ 5 Tablet: Each film coated tablet contains Flunarizine Dihydrochloride BP equivalent to 5 mg Flunarizine.
Imigra™ 10 Tablet: Each film coated tablet contains Flunarizine Dihydrochloride BP equivalent to 10 mg Flunarizine.
Imigra™ 5 Capsule: Each capsule contains Flunarizine Dihydrochloride BP equivalent to 5 mg Flunarizine.
Imigra™ 10 Capsule: Each capsule contains Flunarizine Dihydrochloride BP equivalent to 10 mg Flunarizine
Indication
O Symptomatic treatment of vestibular vertigo & dizziness.
O Peripheral vascular diseases (Intermittent claudication, Raynaud's phenomenon, paresthesia, cold extremities etc.).
O Epilepsy resistant to conventional anti-epileptic therapy.
O Prophylaxis of classic (with aura) or common (without aura) migraine.
Dose and Administration
For vertigo: The recommended maximum daily dose of Flunarizine in the treatment of vertigo is 10 mg daily in adults and 5 mg daily in children (<40 kg).
For epilepsy: An optimal therapeutic dosage in epileptic patients receiving other anti-epileptic drug is 15 mg to 20 mg daily in adults and 5 to 10 mg daily in children.
For migraine prophylaxis: Starting dose is 10 mg daily at night for adult patients less than 65 years of age and 5 mg daily for patients older than 65 years.
Maintenance treatment: If a patient's response is satisfactory and if a maintenance treatment is needed, the dose should be decreased. The patient should have 5 days treatment in a week at the same daily dose and 2 successive drug free days. Treatment should be stopped after 6 months and reinitiated only if the patient relapses.
Or as directed by the physician
